A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice

Bone

Volumn 49, Issue 1, 2011, Pages 122-127

  Plotkin, L I ^a   Bivi, Nicoletta ^a   Bellido, T ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bisphosphonate; Bone strength; Glucocorticoid; Osteoblast; Osteocyte

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; IG 9402; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCALCIN; PREDNISOLONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BIOMECHANICS; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE REMODELING; BONE RESORPTION; DIPHOSPHONATES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLUCOCORTICOIDS; MICE; ORGAN SIZE; OSTEOCLASTS; OSTEOCYTES; SPINE;

EID: 79958736766     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2010.08.011     Document Type: Article

References (34)

1. Jilka R.L., Bellido T., Almeida M., Plotkin L.I., O'Brien C.A., Weinstein R.S., et al. Apoptosis in bone cells. Principles of bone biology 2008, 237-261. Academic Press, New York. J.P. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
2. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004, 75:451-461.
3. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
4. Follet H., Li J., Phipps R.J., Hui S., Condon K., Burr D.B. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007, 40:1172-1177.
5. Kogianni G., Mann V., Ebetino F., Nuttall M., Nijweide P., Simpson H., et al. Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 2004, 75:2879-2895.
6. Plotkin L.I., Lezcano V., Thostenson J., Weinstein R.S., Manolagas S.C., Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008, 23:1712-1721.
7. Bellido T., Plotkin L.I. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011, 49:50-55.
8. Plotkin L.I., Manolagas S.C., Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 2002, 277:8648-8657.
9. Plotkin L.I., Aguirre J.I., Kousteni S., Manolagas S.C., Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of ERK activation. J Biol Chem 2005, 280:7317-7325.
10. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Min Res 1995, 10:1478-1487.
11. Plotkin L.I., Manolagas S.C., Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006, 39:443-452.
12. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
13. Storm T., Steiniche T., Thamsborg G., Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Min Res 1993, 8:199-208.
14. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92:2577-2586.
15. Boyce R.W., Paddock C.L., Gleason J.R., Sletsema W.K., Eriksen E.F. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Min Res 1995, 10:211-221.
16. Van Beek E., Lowik C., Que I., Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Min Res 1996, 11:1492-1497.
17. Brown R.J., Van Beek E., Watts D.J., Lowik C.W., Papapoulos S.E. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J Bone Min Res 1998, 13:253-258.
18. Sanders J.M., Ghosh S., Chan J.M., Meints G., Wang H., Raker A.M., et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 2004, 47:375-384.
19. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003, 278:50259-50272.
20. Erlebacher A., Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996, 132:195-210.
21. Aguirre J.I., Plotkin L.I., Stewart S.A., Weinstein R.S., Parfitt A.M., Manolagas S.C., et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Min Res 2006, 21:605-615.
22. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Min Res 1987, 2:595-610.
23. Weinstein R.S., Jia D., Powers C.C., Stewart S.A., Jilka R.L., Parfitt A.M., et al. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 2004, 145:1980-1987.
24. -δδCT method. Methods 2001, 25:402-408.
25. Kousteni S., Han L., Chen J.R., Almeida M., Plotkin L.I., Bellido T., et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003, 111:1651-1664.
26. Morrison N.A., Shine J., Fragonas J.C., Verkest V., McMenemy M.L., Eisman J.A. 1, 25-Dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 1989, 246:1158-1161.
27. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282.
28. O'Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., Stewart S.A., et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145:1835-1841.
29. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62.
30. Cheung M.S., Glorieux F.H., Rauch F. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. J Bone Miner Res 2009, 24:669-674.
31. Owens J.M., Fuller K., Chambers T.J. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol 1997, 172:79-86.
32. Weinstein R.S., Jilka R.L., Almeida M., Roberson P.K., Manolagas S.C. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 2010, 151:2641-2649.
33. Miao D., He B., Jiang Y., Kobayashi T., Soroceanu M.A., Zhao J., et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 2005, 115:2402-2411.
34. Brumsen C., Hamdy N.A., Papapoulos S.E. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997, 76:266-283.